News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Safety profile and activity of high-dose temozolomide given daily x 3 every 2 weeks in patients with primary brain tumors. Temador was given safely at escalated dosages on days 1-3 and 14-16 every 28 days.


Posted on: 05/26/2002

Safety profile and activity of high-dose temozolomide given daily x 3 every 2 weeks in patients with primary brain tumors

Eric Raymond, Karina Vera, Latifa Djafari, Laure Felizot, Sandrine Faivre, Kamel Djazouli, Institute Gustave Roussy, Villejuif, France; Schering-Plough, Levallois-Perret, France.

Temozolomide (Temodal-TMZ) has shown activity and limited toxicity in patients (pts) with primary brain tumors (PBT) at doses of 150-200 mg/m2/d1-5 q4weeks. We explored safety and activity of a new alternative high-dose intensity regimen of TMZ. TMZ was given orally at escalated dosages on days 1-3 and 14-16 every 28 days (one cycle). Four groups of at least 7 evaluable patients with PBT received TMZ at doses ranging 200-350 mg/m2/day(d) (8mg oral ondansetron 30-60min prior to TMZ). Blood count with differential (NCI-CTC) was assessed weekly for toxicity and brain MRI was performed at baseline then every 3 cycles (McDonalds criteria) for activity. Thirty-eight patients (male/female: 28/10; mean age: 49, range 17-73, PS 0-1: 27) including 10 glioblastomas, 9 astrocytomas, 11 oligodendrogliomas, 5 oligoastrocytomas, 1 ganglioglioma, 1 pineoblastoma, and 1 malignant meningioma were entered. Twenty-four pts had prior surgery including 8 complete resections, 16 partial resections, and 14 stereotaxic biopsies. Thirty-four and 16 pts had prior radiotherapy and chemotherapy, respectively. Median prior chemotherapy number including nitrosoureas was 1 (1-3). Seven (24 cycles), 8 (36 cycles), 12 (44 cycles), and 11 pts (86 cycles) received 200, 250, 300, and 350 mg/m2/d TMZ, respectively. Gr2-3 thrombocytopenia was observed in 1/7, 0/7, 3/11 and 6/10 evaluable pts treated with 200, 250, 300, and 350 mg/m2/d TMZ, respectively. Gr2-3 neutropenia was observed in 2/7, 1/7, 0/11, 3/10 pts treated with 200, 250, 300, and 350 mg/m2/d TMZ, respectively. Gr4 neutropenia (1 febrile) was observed in 2 pts at the dose of 350 mg/m2/d TMZ. Tumor control (partial response-PR+tumor stabilization-SD) was observed in 2/6 (2SD), 4/6 (1PR+3SD), 4/11 (1CR+2PR+1SD), and 10/10 (5PR+5SD) evaluable pts treated with 200, 250, 300, and 350 mg/m2/d TMZ, respectively.

In summary, high-dose intensity 300 mg/m2/dx3 q2w TMZ is safe with evidence of activity in chemonaive and nitrosourea-pretreated pts with PBT.
Source: ASCO 2002 Annual Meeting
Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740